Safety of BNT162b2 and CoronaVac during pregnancy on birth outcomes and neonatal mortality: a cohort study from Brazil
International Journal of Epidemiology · 2023
DOI: 10.1093/ije/dyad120 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift International Journal of Epidemiology, 2023. Verfasst von Pilar Tavares Veras Florentino und 15 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Integração de Dados e Conhecimentos para Saúde, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil. Hauptthemen laut MEDLINE: BNT162 Vaccine, COVID-19, Infant Mortality, Perinatal Death. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Brazilian National Research Council.
Abstract (Originalsprache)
Background
COVID-19 vaccines have been shown to protect pregnant individuals against mild and severe COVID-19 outcomes. However, limited safety data are available for inactivated (CoronaVac) and mRNA (BNT162b2) vaccines during pregnancy regarding their effect on birth outcomes and neonatal mortality, especially in low- and middle-income countries.
Methods
We conducted a retrospective population-based cohort study in Rio de Janeiro, Brazil, with 17 513 singleton live births conceived between 15 May 2021 and 23 October 2021. The primary exposure was maternal vaccination with CoronaVac or mRNA BNT162b2 vaccines and sub-analyses were performed by the gestational trimester of the first dose and the number of doses given during pregnancy. The outcomes were pre-term birth (PTB), small for gestational age (SGA), low birthweight (LBW), low Apgar 5 and neonatal death. We used the Cox model to estimate the hazard ratio (HR) with a 95% CI and applied the inverse probability of treatment weights to generate adjusted HRs.
Results
We found no significant increase in the risk of PTB (HR: 0.98; 95% CI 0.88, 1.10), SGA (HR: 1.09; 95% CI 0.96, 1.27), LBW (HR: 1.00; 95% CI 0.88, 1.14), low Apgar 5 (HR: 0.81; 95% CI 0.55, 1.22) or neonatal death (HR: 0.88; 95% CI 0.56, 1.48) in women vaccinated with CoronaVac or BNT162b2 vaccines. These findings were consistent across sub-analyses stratified by the gestational trimester of the first dose and the number of doses given during pregnancy. We found mild yet consistent protection against PTB in women who received different vaccine platforms during the third trimester of pregnancy (any vaccines, HR: 0.78; 95% CI 0.63, 0.98; BNT162b2, HR: 0.75; 95% CI 0.59, 0.99).
Conclusions
This study provides evidence that COVID-19 vaccination in all trimesters of pregnancy, irrespective of the vaccine type, is safe and does not increase the risk of adverse birth outcomes or neonatal deaths.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centro de Integração de Dados e Conhecimentos para Saúde, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
- Centro de Inteligência Epidemiológica, Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil.
- Instituto de Estudos em Saúde Coletiva, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
- Câmara dos Deputados, Câmara Legislativa do Distrito Federal, Congresso Nacional, Brasília, Brazil.
- Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
- Laboratório de Medicina e Saúde Pública de Precisão, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
ORCID-Profile: Pilar Tavares Veras Florentino, Neil Pearce, Enny Santos da Paixão
Förderung
- Wellcome Trust
- Brazilian National Research Council
Zitieren
APA
Tavares Veras Florentino, P., Cerqueira-Silva, T., Freire De Carvalho, L., Jôse Oliveira Alves, F., De Araújo Oliveira, V., Mateus Oliveira Aguilar, G., De Sousa Prado, R., Soranz, D., Pearce, N., Boaventura, V., Loreiro Werneck, G., Oliveira Penna, G., Lima Barreto, M., Henrique De Oliveira Garcia, M., Barral-Netto, M., & Santos da Paixão, E. (2023). Safety of BNT162b2 and CoronaVac during pregnancy on birth outcomes and neonatal mortality: a cohort study from Brazil. International Journal of Epidemiology. https://doi.org/10.1093/ije/dyad120
Vancouver
Tavares Veras Florentino P, Cerqueira-Silva T, Freire De Carvalho L, Jôse Oliveira Alves F, De Araújo Oliveira V, Mateus Oliveira Aguilar G, et al. Safety of BNT162b2 and CoronaVac during pregnancy on birth outcomes and neonatal mortality: a cohort study from Brazil. International Journal of Epidemiology. 2023. doi:10.1093/ije/dyad120
BibTeX
@article{TavaresVerasFlorentino2023,
author = {Tavares Veras Florentino, Pilar and Cerqueira-Silva, Thiago and Freire De Carvalho, Luciana and Jôse Oliveira Alves, Flávia and De Araújo Oliveira, Vinicius and Mateus Oliveira Aguilar, Gislani and De Sousa Prado, Rodrigo and Soranz, Daniel and Pearce, Neil and Boaventura, Viviane and Loreiro Werneck, Guilherme and Oliveira Penna, Gerson and Lima Barreto, Mauricio and Henrique De Oliveira Garcia, Márcio and Barral-Netto, Manoel and Santos da Paixão, Enny},
title = {Safety of BNT162b2 and CoronaVac during pregnancy on birth outcomes and neonatal mortality: a cohort study from Brazil},
journal = {International Journal of Epidemiology},
year = {2023},
doi = {10.1093/ije/dyad120}
}
EUVIMED